Autologous Dendritic Cell Vaccine in Kidney Cancer

This trial is testing a personalized cancer vaccine made from a patient's own immune cells (dendritic cells) in people with non-metastatic clear cell kidney cancer (renal cell carcinoma) who are having surgery to remove the tumor. After the kidney is removed, immune cells from the patient's blood are used to create a custom vaccine designed to train the immune system to recognize and attack any remaining cancer cells. **You may be eligible if...** - You are 18 or older with confirmed clear cell renal (kidney) cancer that has not spread - Your cancer can be surgically removed - You have a specific immune type (HLA-A2 positive) if receiving the vaccine - Your blood counts and organ function are adequate - Your ECOG performance status is 0 or 1 (fully active or mostly active) **You may NOT be eligible if...** - Your cancer has spread to other organs (metastatic) - You are not HLA-A2 positive (required for the vaccine group) - You have autoimmune disease or are on immunosuppressive drugs - You have had prior systemic therapy for kidney cancer - You have significant heart, liver, or kidney dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.